Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00806806
Other study ID # SKY0402C109
Secondary ID
Status Completed
Phase Phase 1
First received December 9, 2008
Last updated August 31, 2010
Start date October 2008
Est. completion date February 2009

Study information

Verified date August 2010
Source Pacira Pharmaceuticals, Inc
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Given as a single perioperative injection, SKY0402 could provide adequate, continuous, and extended pain relief that could greatly simplify postoperative pain management, reduce the need for repeated administration, and minimize episodes of breakthrough pain.


Description:

Subjects will be given either SKY0402 or placebo in response to a noxious stimulus, and the time to onset will be recorded.


Recruitment information / eligibility

Status Completed
Enrollment 128
Est. completion date February 2009
Est. primary completion date February 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

Subjects eligible for study entry will meet the following criteria:

- Male or female, ages at least 18 years and not over 55 years.

- Body mass index (BMI) within the range 20.0 to 30.0 kg/m2, inclusive.

- Applies to females only: Female subjects of childbearing potential with a nonsterilized male sexual partner must agree to use a hormonal contraceptive, barrier contraceptive with additional spermicide, or an intrauterine device beginning > 30 days prior to the first dosing and continuing until > 7 days after the end of the study. Female subjects who are postmenopausal must have been postmenopausal for > 1 year if they wish not to use contraceptives.

- Good general health, evidenced by a lack of significantly abnormal findings on medical history and screening assessments.

- Pain intensity score of > 30 mm on a VAS after incision and application of an 18% acetic acid solution to nontreated skin (i.e., not infiltrated with any test or control article) at Screening.

- Able and willing to comply with all study visits and procedures, including returning as scheduled for the second treatment visit.

- Able to speak, read, and understand the language of the ICF, study questionnaires, and other instruments used for collecting subject-reported outcomes, in order to enable accurate and appropriate responses to pain scales and other required study assessments.

- Willing and capable of providing written informed consent.

Exclusion Criteria:

A subject will not be eligible for the study if he or she meets any of the following criteria:

- A history of hypersensitivity to amide type local anesthetics.

- Pregnancy, nursing, or planning to become pregnant during the course of the study.

- Any current conditions that might interfere with pain assessments, including current pain.

- Conditions of the skin or neurological abnormalities that might alter pain sensitivity. These include excessive scarring, burns, skin grafts, and trauma. Tattoos are permitted.

- A history of keloid formation.

- A coagulopathy or use of medications that might enhance bleeding.

- Use of any of the following medication within the times specified before study drug administration:

- Long-acting opioid mediations within 3 days.

- Any opioid medication within 24 hours.

- Any analgesic medication within 12 hours.

- Consumption of alcohol within 24 hours before either treatment visit.

- Any condition that, in the opinion of the Investigator, renders a subject unsuitable for participation in the study. NOTE: The specific reason(s) for exclusion will be documented in the Screening Log.

- Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.

Minor deviations in eligibility criteria are permitted if approved by the Pacira Medical Monitor in agreement with the Investigator prior to dosing.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care


Related Conditions & MeSH terms


Intervention

Drug:
SKY0402
Local administration of SKY0402 followed by noxious stimulus
Placebo
Local administration of Placebo followed by noxious stimuli

Locations

Country Name City State
United States The Ohio State University College of Medicine, Dept of Pharmacology Columbus Ohio

Sponsors (1)

Lead Sponsor Collaborator
Pacira Pharmaceuticals, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary time to onset of action 15 minutes Yes
Secondary time to onset bewteen 15 and 30 minutes Yes
See also
  Status Clinical Trial Phase
Completed NCT02516059 - Early Postoperative Administration of Oxycodone +/- Naloxone and Duration of Epidural Analgesia Phase 4
Terminated NCT01736358 - The Use of Intranasal Ketoralac for Pain Management (Sprix) Phase 4
Terminated NCT02143141 - Low Pain Prediction in Cesarean Section Patients Phase 4
Recruiting NCT05011084 - Combined Cryotherapy With Compression Versus Cryotherapy Alone After Orthopaedic Surgery N/A
Terminated NCT03428984 - Study in Adult Subjects Undergoing Posterolateral Thoracotomy Phase 1
Completed NCT04371341 - A Comparative Study Between Different Volumes During Erector Spinae Block for Pain Control N/A
Recruiting NCT06298370 - The Efficacy of Combined Intrathecal Morphine and PENG Block on Postoperative Pain in Hip Arthroplasty N/A
Completed NCT06028061 - Evaluation of Effectivity of Quadratus Lumborum Blocks With Adjuvant N/A
Completed NCT05401916 - Efficacy of Intravenous Ibuprofen and Paracetamol on Postoperative Pain and Tramadol Consumption in Shoulder Surgery N/A
Terminated NCT03927911 - Phase 4 Study in Adult Subjects Undergoing Posterior Lumbar Spine Surgeries Phase 4
Completed NCT01344213 - Pregabalin, Celecoxib, Total Knee Arthroplasty and Intrathecal Morphine Phase 4
Completed NCT04434339 - Ultrasound-guided Erector Spinae Plane Block Versus Transversus Abdominis Plane Block for Postoperative Analgesia of Adult Patients Undergoing Ovarian Cancer Surgery N/A
Recruiting NCT02997215 - Intravenous Lidocaine and Postoperative Pain Management Phase 4
Completed NCT01070108 - Escalating Ketamine Doses and Pre-emption N/A
Not yet recruiting NCT06148168 - Magnesium Sulphate in Oblique Subcostal TAP Block Phase 2/Phase 3
Terminated NCT03015961 - Phase 4, Controlled Study in Adult Subjects Undergoing Primary, 1-2 Level, Open Lumbar Spinal Fusion Surgery Phase 4
Completed NCT01726686 - Pain Treatment After TKA With LIA and Intra-articular Continuous Infusion Pump Phase 4
Not yet recruiting NCT04525963 - The Effect of Operating Room Nurse Visit Prior to Cardiac Surgery on Patients's Anxiety, Pain and Analgesic Use N/A
Completed NCT03437707 - Efficacy of Intravenous Ibuprofen and Paracetamol on Postoperative Pain and Morphine Consumption in Lumbar Disc Surgery N/A
Completed NCT04691856 - Efficacy of Intravenous Paracetamol and Ibuprofen on Postoperative Pain and Morphine Consumption in Hysterectomy N/A